George A. Fisher Jr.

Publications

• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
  Le, D. T., Uram, J. N., Wang, H., BARTLETT, B. R., Kemberling, H., & Diaz, L. A. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. NEW ENGLAND JOURNAL OF MEDICINE, 372(26), 2509-2520.
• Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
  Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., & Koong, A. C. (2015). Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma. CANCER, 121(7), 1128-1137.
• Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
  Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., & Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918-925.
• Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness Worhunsky, D. J., Krampitz, G. W., Poullos, P. D., Visser, B. C., Kunz, P. L., & Poultsides, G. A. (2014). Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB, 16(4), 304-311.
  
• Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors Qadan, M., Ma, Y., Visser, B. C., Kunz, P. L., Fisher, G. A., & Poultsides, G. A. (2014). Reassessment of the Current American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 218(2), 188-195.
  
• Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer Garrett, C. R., Bekaii-Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., & Goldberg, R. M. (2013). Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer. CANCER, 119(24), 4223-4230.
  
• Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., & Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631-1638.
  
• Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Cherepanov, D., & Broder, M. S. (2013). Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process. PANCREAS, 42(3), 397-404.
  
• Capecitabine-Induced Chest Pain Relieved by Diltiazem Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623-1626.
  
• Long-Term Survivors of Gastric Cancer: A California Population-Based Study Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507-3515.
  
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., & Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128-1139.
  
• Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors. Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Anthony, L. B., & Broder, M. S. (2012). Medical treatment consensus in unresectable midgut gastrointestinal neuroendocrine tumors. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., & Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420-1425.
  
• Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer Knox, S., Fisher, G., Wessels, B., Cho, C., Hernandez, M. C., & Goris, M. (2004). Phase I study of I-131-chimeric(ch) TNT-1/B antibody for the treatment of advanced colorectal cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 19(4), 528-528.
  
• The Stanford experience with preoperative chemoradiation using CPT-11 and 5-FU in locally advanced rectal cancer: Toxicities and outcomes Tillman, G. F., Fisher, G., Cho, C., Ford, J. M., Mehta, V. K., & Koong, A. (2004). The Stanford experience with preoperative chemoradiation using CPT-11 and 5-FU in locally advanced rectal cancer: Toxicities and outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60(1), S417-S418.
  
• A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. EUROPEAN JOURNAL OF CANCER, 38, S63-S63.
  
• The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48-P48.
  
• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound staged T3 rectal cancer Mehta, V. K., Poen, J. C., Ford, J., Young, H., Cho, C., & Fisher, G. (2001). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound staged T3 rectal cancer. CANCER JOURNAL, 7(6), 539-539.
  
• Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization. Millan, M. T., Lai, K. M., Keeffe, E. B., Fisher, G. A., Razavi, M. K., & So, S. Ks. (2000). Liver transplantation for hepatocellular carcinoma and the role of preoperative chemoembolization. TRANSPLANTATION, 69(8), S215-S215.
  
• Clinical decision making based on radionuclide determined ejection fraction in oncology patients Peng, N. J., Advani, R., Kopiwoda, S., Fisher, G., & Strauss, H. W. (1997). Clinical decision making based on radionuclide determined ejection fraction in oncology patients. JOURNAL OF NUCLEAR MEDICINE, 38(5), 702-705.
  
• REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY LEYLANDJONES, B., Dalton, W., Fisher, G. A., & Sikic, B. I. (1993). REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY. CANCER, 72(11), 3484-3488.
  
• Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer Lam, M. Geh., Louie, J. D., Abdelmaksoud, M. Hk., Fisher, G. A., Cho-Phan, C. D., & Sze, D. Y. (2014). Limitations of Body Surface Area-Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 25(7), 1085-1093.
  
• Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., & Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295-2303.
  
• A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer Cabebe, E. C., Fisher, G. A., & Sikic, B. I. (2012). A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 30(3), 1082-1087.
  
• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013-1020.
  
• Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595-E601.
  
• HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., & Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13-24.
  
• Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., & Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971-977.
  
• Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., & Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342-3351.
  
• Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., & Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724-732.
  
• F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343-347.
  
• Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., & Yao, J. C. (2011). Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 934-943.
  
• Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., & Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179-5187.
  
• Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., & Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943-3952.
  
• Pathological response after chemoradiation for T3 rectal cancer Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24-E30.
  
• Pathological response after chemoradiation for T3 rectal cancer. Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal disease , 12(7 Online), e24-30.
  
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., & Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376-381.
  
• Multimodality treatment with intensity modulated radiation therapy for esophageal cancer La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., & Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300-308.
  
• Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and experimental gastroenterology, 3, 79-86.
  
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., & Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.
  
• Impaired interferon signaling is a common immune defect in human cancer Critchley-Thorne, R. J., Simons, D. L., Yan, N., Miyahira, A. K., Dirbas, F. M., & Lee, P. P. (2009). Impaired interferon signaling is a common immune defect in human cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(22), 9010-9015.
  
• Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., & Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665-672.
  
• Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., & Koong, A. C. (2008). Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 678-686.
  
• A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer Fischer, Ga., Kuo, T., Ramsey, M., Schwartz, E., Rouse, Rv., & Sikic, B. I. (2008). A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. CLINICAL CANCER RESEARCH, 14(21), 7074-7079.
  
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613-1618.
  
• Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies Cupp, J. S., Koong, A. C., Fisher, G. A., NORTON, J. A., & Goodman, K. A. (2008). Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies. CLINICAL ONCOLOGY, 20(1), 69-75.
  
• Phase H study of imatinib in unresectable hepatocellular carcinoma Lin, A. Y., Fisher, G. A., So, S., Tang, C., & Levitt, L. (2008). Phase H study of imatinib in unresectable hepatocellular carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(1), 84-88.
  
• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., & Zalcberg, J. (2007). NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network , 5, S1-29.
  
• Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer Cabebe, E., & Fisher, G. A. (2007). Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 16(4), 467-476.
  
• Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., & Knox, S. J. (2006). Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 21(3), 243-256.
  
• Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies Cho, C. D., Fisher, G. A., Halsey, J., & Sikic, B. I. (2006). Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. INVESTIGATIONAL NEW DRUGS, 24(2), 117-123.
  
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968-1973.
  
• Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Kuo, T., & Fisher, G. A. (2005). Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clinical colorectal cancer, 5, S62-70.
  
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., & Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467-477.
  
• Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., & Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320-323.
  
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.
  
• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer Wakelee, H., & Fisher, G. A. (2005). A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 23(3), 241-242.
  
• Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma Lin, A. Y., Brophy, N., Fisher, G. A., So, S., Biggs, C., & Levitt, L. (2005). Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. CANCER, 103(1), 119-125.
  
• Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., & Bastidas, J. A. (2004). Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1017-1021.
  
• A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., & Sikic, B. I. (2004). A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. CANCER, 100(2), 321-326.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., & Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S-6103S.
  
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., & Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187-5194.
  
• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., & Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132-137.
  
• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Fong, L., Hou, Y. F., Rivas, A., Benike, C., Yuen, A., & Engleman, E. G. (2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 98(15), 8809-8814.
  
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221-1229.
  
• Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155-159.
  
• Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis Lai, K. M., MILLAN, M., Razavi, M., Keeffe, E. B., Prapong, W., & So, S. Ks. (2001). Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis. TRANSPLANTATION PROCEEDINGS, 33(1-2), 1490-1491.
  
• Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., & Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27-35.
  
• Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., & Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52-58.
  
• Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65-69.
  
• Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483-1487.
  
• Pancreatic tumors show high levels of hypoxia Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., & Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(4), 919-922.
  
• Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., & Sikic, B. I. (2000). Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 45(4), 305-311.
  
• Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., & Sikic, B. I. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. CLINICAL CANCER RESEARCH, 5(11), 3357-3363.
  
• Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil Poen, J. C., Collins, H. L., Niederhuber, J. E., Oberhelman, H. A., Vierra, M. A., & Goffinet, D. R. (1998). Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 40(1), 93-99.
  
• Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., & Chen, G. (1997). Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 40, S13-S19.
  
• Pharmacological considerations in the modulation of multidrug resistance Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. EUROPEAN JOURNAL OF CANCER, 32A(6), 1082-1088.
  
• Drug resistance in clinical oncology and hematology. Introduction. Fisher, G. A., & Sikic, B. I. (1995). Drug resistance in clinical oncology and hematology. Introduction. Hematology/oncology clinics of North America, 9(2), xi-xii.
  
• CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE Fisher, G. A., & Sikic, B. I. (1995). CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 363-382.
  
• The reversal of multidrug resistance. Fisher, G. A., Lum, B. L., & Sikic, B. I. (1995). The reversal of multidrug resistance. Cancer treatment and research, 78, 45-70.
  
• MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG) Li, G. C., Fessenden, P., Hahn, G. M., Fisher, G., Luxton, G., & Bagshaw, M. A. (1994). MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG). INTERNATIONAL JOURNAL OF HYPERTHERMIA, 10(3), 361-370.
  
• PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., & Sikic, B. I. (1994). PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 12(4), 835-842.
  
• Clinical reversal of multidrug resistance. Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., & Halsey, J. (1994). Clinical reversal of multidrug resistance. Cancer treatment and research, 73, 149-165.
  
• CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., & Sikic, B. I. (1993). CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS. CANCER, 72(11), 3502-3514.
  
• THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., & Sikic, B. I. (1993). THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD. ELSEVIER SCIENCE PUBL B V.
  
• PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., & Sikic, B. I. (1992). PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 10(10), 1624-1634.
  
• DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS Anderson, R. L., Shiu, E., Fisher, G. A., & Hahn, G. M. (1988). DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 54(2), 285-298.
  
• CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING RICE, G. C., Fisher, K. A., Fisher, G. A., & Hahn, G. M. (1987). CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING. RADIATION RESEARCH, 112(2), 351-364.
  
• INDUCTION OF THERMOTOLERANCE AND EVIDENCE FOR A WELL-DEFINED, THERMOTROPIC COOPERATIVE PROCESS Li, G. C., Fisher, G. A., & Hahn, G. M. (1982). INDUCTION OF THERMOTOLERANCE AND EVIDENCE FOR A WELL-DEFINED, THERMOTROPIC COOPERATIVE PROCESS. RADIATION RESEARCH, 89(2), 361-368.
  
• MODIFICATION OF THE THERMAL RESPONSE BY D2O .2. THERMOTOLERANCE AND THE SPECIFIC-INHIBITION OF DEVELOPMENT Li, G. C., Fisher, G. A., & Hahn, G. M. (1982). MODIFICATION OF THE THERMAL RESPONSE BY D2O .2. THERMOTOLERANCE AND THE SPECIFIC-INHIBITION OF DEVELOPMENT. RADIATION RESEARCH, 92(3), 541-551.
  
• MODIFICATION OF THE THERMAL RESPONSE BY D2O .1. CELL-SURVIVAL AND THE TEMPERATURE SHIFT Fisher, G. A., Li, G. C., & Hahn, G. M. (1982). MODIFICATION OF THE THERMAL RESPONSE BY D2O .1. CELL-SURVIVAL AND THE TEMPERATURE SHIFT. RADIATION RESEARCH, 92(3), 530-540.